Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ispinesib · 4 trials · 4 indications
Overall tumor response rate, was defined as the percentage of participants achieving either a complete response (CR) or partial response (PR), stable disease (SD), or progressive disease (PD). It was assessed by Computer tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Response and progression was evaluated in this study using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. The target lesions (TLs): CR, Disappearance of all TLs; PR where at least a 30% decrease in the sum of the longest diameter (LD) of TLs, taking as reference the baseline sum LD; PD : At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
| Arm | Type | Description |
|---|---|---|
| SB-715992 | EXPERIMENTAL | Females with advanced or metastatic breast cancer were administered Ispinesib |
| Name | Type | Description |
|---|---|---|
| Ispinesib | DRUG | - |
| Capecitabine | DRUG | - |
Inclusion criteria: * Must have a screening CA-125 of greater than or equal to 40 U/ml. * Must have received only one prior platinum/taxane-based chemotherapy regimen. * Blood tests will be done to check if blood counts are adequate for taking part in the study. Exclusion criteria: * Received mor...
Ispinesib is an investigational small molecule being studied for the treatment of solid tumor cancers, including non-small-cell lung cancer, ovarian cancer, and breast cancer. It has been evaluated in clinical trials for these oncology indications.
Ispinesib is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The drug is currently in clinical development for oncology indications.
Ispinesib has been studied in Phase 2 clinical trials for non-small-cell lung cancer, breast cancer, and ovarian cancer, and in a Phase 1 trial for solid tumors. It is an investigational drug and has not been approved by regulatory authorities.
Ispinesib has been evaluated in several completed clinical trials. NCT00085813 studied it in patients with advanced or metastatic non-small-cell lung cancer. NCT00089973 examined it in breast cancer. NCT00097409 tested it in platinum-taxane-refractory or resistant relapsed ovarian cancer. NCT00119171 evaluated it in combination with capecitabine in solid tumors.
Ispinesib is also known by the code name SB-715992. This alternative name may be used in scientific literature and clinical trial registries to refer to the same investigational drug.
Ispinesib is a small molecule that targets kinesin spindle protein, an enzyme essential for cell division. By inhibiting this protein, the drug is designed to disrupt mitosis in cancer cells, potentially slowing tumor growth.